A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2013
At a glance
- Drugs AZD 4877 (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 29 Aug 2012 Planned number of patients changed from 50 to 54 as reported by German Clinical Trials Register.
- 29 Aug 2012 New source identified and integrated (DRKS00004052: German Clinical Trials Register).
- 23 Nov 2010 Additional lead trial investigator (Robert Jones) added as reported by United Kingdom Clinical Research Network record.